Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
0.975
-0.045 (-4.41%)
At close: Jan 31, 2025, 4:00 PM
0.980
+0.005 (0.51%)
After-hours: Jan 31, 2025, 5:12 PM EST
Immunic Employees
Immunic had 77 employees as of December 31, 2023. The number of employees increased by 11 or 16.67% compared to the previous year.
Employees
77
Change (1Y)
11
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,258,494
Market Cap
87.83M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
IMUX News
- 25 days ago - Immunic Highlights 2024 Accomplishments and Upcoming Milestones - PRNewsWire
- 2 months ago - Immunic, Inc. to Participate in Investor Conference in December - PRNewsWire
- 2 months ago - Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology - PRNewsWire
- 3 months ago - Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - PRNewsWire
- 3 months ago - Immunic to Participate in Industry, Scientific and Investor Conferences in November - PRNewsWire
- 3 months ago - Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis - PRNewsWire